Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Apr;25(4):417–424. doi: 10.1111/j.1365-2125.1988.tb03324.x

Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man.

A H Deering 1, J G Riddell 1, D W Harron 1, R G Shanks 1
PMCID: PMC1387802  PMID: 3382587

Abstract

1. The effects of the acute and chronic administration of the alpha 1-adrenoceptor antagonist alfuzosin (5 mg twice daily for 7 days) on baroreflex function, physiological tremor and sedation (visual analogue scale) were investigated in six healthy volunteers. 2. Phenylephrine-systolic pressure dose-response curves were shifted (P less than 0.05) to the right by alfuzosin compared with placebo on day 1, and on day 8 prior to the administration of alfuzosin indicating significant alpha-adrenoceptor blockade over 24 h with 5 mg twice daily administration. 3. Baroreflex sensitivity (delta R-R ms mmHg-1 systolic arterial pressure) was reduced (P less than 0.05) by alfuzosin compared with placebo on day 1 (13.8 +/- 2.6 vs 20.6 +/- 3.6 ms mmHg-1) and on day 8 (13.4 +/- 1.7 vs 21.1 +/- 2.7 ms mmHg-1). 4. Maximum power (microV2) or frequency (Hz) of physiological tremor did not change 2 h after alfuzosin administration on day 1 (13.7 +/- 4.4 microV2, 9.2 +/- 0.3 Hz) or day 8 (11.5 +/- 4.3 microV2, 10.0 +/- 0.4 Hz) compared with placebo on day 1 (16.9 +/- 7.5 microV2, 10.0 +/- 0.4 Hz) and day 8 (17.3 +/- 5.7 microV2, 10.2 +/- 0.8 Hz). 5. Alfuzosin 5 mg twice daily did not cause sedation on day 1 or day 8. 6. In conclusion the reduction in baroreflex sensitivity with the alpha-adrenoceptor antagonist alfuzosin may contribute to its antihypertensive activity in reducing the reflex tachycardia associated with its hypotensive action.

Full text

PDF
417

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham G. J., Ahmed S. S., Verghese K. G. Effects of cerebroventricular perfusion of alpha and beta adrenergic blocking agents on carotid occulsion response. Arch Int Pharmacodyn Ther. 1970 Nov;188(1):105–111. [PubMed] [Google Scholar]
  2. Algate D. R., Rashid S., Waterfall J. F. Cardioregulatory properties of indoramin in the rat. J Pharm Pharmacol. 1981 Apr;33(4):236–239. doi: 10.1111/j.2042-7158.1981.tb13765.x. [DOI] [PubMed] [Google Scholar]
  3. Awan N. A., Miller R. R., Miller M. P., Specht K., Vera Z., Mason D. T. Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output. Am J Med. 1978 Jul;65(1):146–154. doi: 10.1016/0002-9343(78)90703-9. [DOI] [PubMed] [Google Scholar]
  4. CARLSTEN A., FOLKOW B., GRIMBY G., HAMBERGER C. A., THULESIUS O. Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand. 1958 Nov 18;44(2):138–145. doi: 10.1111/j.1748-1716.1958.tb01615.x. [DOI] [PubMed] [Google Scholar]
  5. Graham R. M., Thornell I. R., Gain J. M., Bagnoli C., Oates H. F., Stokes G. S. Prazosin: the first-dose phenomenon. Br Med J. 1976 Nov 27;2(6047):1293–1294. doi: 10.1136/bmj.2.6047.1293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harron D. W., Kerr M. J., Shanks R. G. Investigation into mechanism of lack of reflex tachycardia in response to hypotensive action of indoramin in dogs. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):596–600. doi: 10.1097/00005344-198407000-00007. [DOI] [PubMed] [Google Scholar]
  7. Harron D. W., Nicholls D. P., Shanks R. G. Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man? Br J Clin Pharmacol. 1985 Feb;19(2):266–271. doi: 10.1111/j.1365-2125.1985.tb02642.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lewis P. J., George C. F., Dollery C. T. Clinical evaluation of indoramin, a new antihypertensive agent. Eur J Clin Pharmacol. 1973 Dec;6(4):211–216. doi: 10.1007/BF00644733. [DOI] [PubMed] [Google Scholar]
  9. Mai J., Olsen R. B. Depression of essential tremor by alpha-adrenergic blockade. J Neurol Neurosurg Psychiatry. 1981 Dec;44(12):1171–1171. doi: 10.1136/jnnp.44.12.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McAllister H. G., Armstrong G. A., McClelland R. J., Linggard R. Data acquisition in neurophysiology. A flexible microcomputer system for recording neurophysiological data. Br J Audiol. 1983 Nov;17(4):275–277. doi: 10.3109/03005368309081489. [DOI] [PubMed] [Google Scholar]
  11. Miller R. R., Awan N. A., Maxwell K. S., Mason D. T. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977 Aug 11;297(6):303–307. doi: 10.1056/NEJM197708112970604. [DOI] [PubMed] [Google Scholar]
  12. Mitchell M. R., Powell T., Terrar D. A., Twist V. W. Ryanodine prolongs Ca-currents while suppressing contraction in rat ventricular muscle cells. Br J Pharmacol. 1984 Jan;81(1):13–15. doi: 10.1111/j.1476-5381.1984.tb10735.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nicholls D. P., O'Connor P. C., Harron D. W., Leahey W. J., Shanks R. G. Differential blockade of alpha-adrenoceptors by indoramin. Br J Clin Pharmacol. 1984 Jun;17(6):719–728. doi: 10.1111/j.1365-2125.1984.tb02409.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ramage A. G. The effect of prazosin, indoramin and phentolamine on sympathetic nerve activity. Eur J Pharmacol. 1984 Nov 27;106(3):507–513. doi: 10.1016/0014-2999(84)90054-2. [DOI] [PubMed] [Google Scholar]
  15. Royds R. B., Coltart D. J., Lockhart J. D. Pharmacologic studies of indoramin in man. Clin Pharmacol Ther. 1972 May-Jun;13(3):380–392. doi: 10.1002/cpt1972133380. [DOI] [PubMed] [Google Scholar]
  16. Sasso E. H., O'Connor D. T. Prazosin depression of baroreflex function in hypertensive man. Eur J Clin Pharmacol. 1982;22(1):7–14. doi: 10.1007/BF00606418. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES